Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early rhythm-control therapy after acute ischemic stroke in patients with atrial fibrillation
NL-OMON59595Phase 4Not yet recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of propafenone in Atrial fibrillation (AFib) and ischemic stroke (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Primary composite cardiovascular outcome. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
propafenone
03
Conditions
Atrial fibrillation (AFib)ischemic stroke
Beyond the preview
Go deeper on NL-OMON59595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59595.